GRAIL Shares Swing 16% Down, Then Rebound 11.5% After Galleri Trial Data
GRAL•Goldman Sachs initiated Neutral coverage on GRAIL with shares at $66.55 after the Galleri test trial failed to reduce late-stage cancer diagnoses, triggering a 16% drop. Subsequent data showing a decline in Stage IV diagnoses and detection of over 150 cancer types propelled an 11.5% rebound in the stock.
1. Goldman Sachs Initiates Neutral Coverage
On June 5, Goldman Sachs began coverage of GRAIL with a Neutral rating, valuing the biotechnology firm at $66.55 per share. The stance reflects balanced expectations for the Galleri multi-cancer early detection test amid mixed clinical results.
2. Galleri Trial Misses Primary Endpoint
A major clinical trial in partnership with England’s National Health Service did not meet its primary goal of significantly reducing late-stage cancer diagnoses, leading to an immediate 16% decline in GRAIL’s share price as investors reevaluated the test’s impact.
3. Data Shows Stage IV Reduction and 150+ Cancer Types
GRAIL presented further results indicating the Galleri test reduces the most advanced Stage IV cancer diagnoses and identifies over 150 cancer types. Management emphasizes this diagnostic utility as a complement to existing screening methods.
4. Stock Volatility: 16% Drop and 11.5% Rebound
After the initial sell-off, the stock rebounded 11.5% as investors responded to the positive Stage IV data. GRAIL now trades at $66.55 with a market capitalization of $2.86 billion and a 52-week range of $29.95 to $118.84, underscoring ongoing volatility.
